This CME has expired.
For a list of active online CME, please click here.
CME Information
Up to 3 hours of AMA PRA Category 1 Credit™
Release date: September 2007 Valid through: October 2008
Course Material: CME Monograph (PDF)
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This educational activity is intended for oncologists, thoracic surgeons, radiologists and other medical professionals who assess, counsel, and treat lung cancer patients.
Learning Objectives
After successfully completing this CME activity, participants should be able to discuss treatment options for early-stage lung cancer patients, including:
- Key elements of a preoperative workup
- Pros/cons of using radiofrequency ablation to treat poor surgical risk patients
- Appropriate use of chemotherapy and radiation therapy in stage II and III lung cancer
- Appropriate use of chemotherapy in treating stage Ia and Ib lung cancer
- Information needed to assess potential future role of adjuvant targeted therapy
Educational Need
Treating early-stage lung cancer is especially challenging, as patients often present while they still feel healthy, and it can be difficult to assess when the benefits of initiating treatment will outweigh the negative effects of intervention. Medical professionals who counsel and treat patients with early-stage disease need to be aware of the most current data and recommendations for assessing and determining the timing and course of treatment for these patients.
Accreditation and Credit Designation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity. InforMEDical designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Each physician should claim credit commensurate with the extent of his/her participation in the activity.
Faculty Disclosure Declarations
The program faculty have reported financial relationships with commercial pharmaceutical, device, and biotechnology companies as follows: Christopher G. Azzoli: Research support: Allos Therapeutics, Genentech, sanofi-aventis. Damian E. Dupuy: Speakers’ Bureau: Valleylab; Grant support: Endocare, Veran Medical; Stockholder: Veran Medical. Armin Ernst: Grant Support: Karl Stoiz Endoscopy America, Olympus; Honorarium: Axcan Pharma. David H. Harpole, Jr: Nothing to disclose. Rebecca Suk Heist: Nothing to disclose. Michael Lanuti: Nothing to disclose. Thomas J Lynch, Jr: Speakers’ Bureau: AstraZeneca, Eli Lilly, Genentech, OSI, sanofi-aventis; Adviser: Boehringer Ingelheim, ImClone, sanofi-aventis; Consultant: Genentech, Millennium, Telik; Royalties: Genzyme.
This educational activity may contain discussion of investigational uses of agents, devices, or diagnostic tools that have not been approved for use by the US Food and Drug Administration. The opinions expressed in the activity are those of the authors and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discus- sion of approved indications, contraindications, contradictions, and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device, or diagnostic tool mentioned in this educational activity.